TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
CommunityDashboard
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·May 4, 2026

Twist Bioscience Corporation (TWST) drops on earnings misses

Twist Bioscience Corporation (TWST) drops 5.5% after reporting earnings misses, as investors react to weaker-than-expected results and reassess the stock's near-term outlook.

Earnings FlashTWSTHealthcareMedical - Diagnostics & Research
By TickerSpark·May 4, 2026·2 min read
Twist Bioscience Corporation (TWST) drops on earnings misses
▌Key Takeaway
Twist Bioscience Corporation (TWST) fell 5.50% after reporting a wider-than-expected quarterly loss, with EPS of -0.71 versus -0.54 expected. Revenue narrowly beat estimates at $0.11 billion, but the market focused on the second straight earnings miss and the lack of clear margin improvement.

Twist Bioscience Corporation (TWST) drops after earnings miss

Twist Bioscience Corporation (TWST) missed on EPS and narrowly beat on revenue, posting EPS of -0.71 versus -0.54 expected and revenue of $0.11B versus $0.11B expected, while the stock fell 5.50% in regular-session trading to $57.08.

Key Numbers

  • EPS: -0.71 vs -0.54 estimate, a miss.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $0.11B vs $0.11B estimate, a beat.
  • Stock reaction: TWST closed at $57.08, down 5.50% in regular-session trading from the prior close of $60.40.
  • Intraday range: shares traded between $56.01 and $59.99.
  • Recent earnings trend: this follows a smaller EPS miss in the prior quarter, when TWST reported -0.50 versus -0.48 estimated on 2026-02-02.

    • Profit pressure outweighed the revenue beat

    The market focused on profitability. Twist Bioscience beat on revenue, but the EPS miss was wider and landed after a prior-quarter miss as well. For a $3.5B growth company, that is usually enough to pressure the stock, especially when the top-line beat is only slight.

    The recent pattern is mixed. Twist beat EPS in two of the three quarters before this report, but it has now missed in back-to-back quarters. That shifts attention back to cost control and operating leverage. In plain English, investors want revenue growth to turn into smaller losses, not bigger disappointment.

    The 5.50% drop in regular-session trading shows the market treated this as a margin story, not a sales story. When a company clears the revenue bar but still gets sold, investors are usually telling management that execution below the gross line matters more right now.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    Twist Bioscience delivered enough revenue to edge past estimates, but the deeper EPS miss and a second straight quarterly shortfall sent TWST lower and kept the focus on profitability.

    Read the full TWST research report
    ▌Common Questions

    Frequently asked questions

    +Why did Twist Bioscience stock drop after earnings?
    Twist Bioscience Corporation (TWST) fell because its EPS miss was larger than expected, even though revenue slightly beat estimates. Investors focused on profitability, and the stock closed down 5.50% at $57.08.
    +Did Twist Bioscience beat revenue and miss earnings in the latest quarter?
    Yes. Twist Bioscience reported revenue of $0.11 billion versus $0.11 billion expected, but EPS came in at -0.71 compared with the -0.54 estimate. The market treated the earnings miss as the more important result.
    +How much did TWST stock move after the earnings report?
    TWST closed at $57.08, down 5.50% in regular-session trading from the prior close of $60.40. Shares traded between $56.01 and $59.99 during the session.
    +What does Twist Bioscience's earnings miss mean for investors?
    The report suggests investors are still waiting for revenue growth to translate into better operating leverage and smaller losses. With back-to-back EPS misses, the market is likely to stay focused on cost control and margin improvement.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on TWST?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the TWST report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full TWST research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the TWST report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on TWST

    More to read

    All articles
    Twist Bioscience Corporation (TWST) rises on deep earnings analysis
    TWST

    Twist Bioscience Corporation (TWST) rises on deep earnings analysis

    Twist Bioscience Corporation (TWST) rose after a mixed quarter that featured an EPS miss but a revenue beat, continued sequential growth, and improving segment momentum. This deep dive examines the margin expansion, adjusted EBITDA breakeven path, and why investors focused on the bigger operating picture.

    Aug 3·7 min
    Twist Bioscience Corporation (TWST) rises on earnings misses
    TWST

    Twist Bioscience Corporation (TWST) rises on earnings misses

    Twist Bioscience Corporation (TWST) rises after reporting earnings misses, with shares up 5.5% as investors react to the latest quarterly results.

    Aug 3·2 min
    Twist Bioscience (TWST): Growth Engine, But Valuation Is Rich
    TWST

    Twist Bioscience (TWST): Growth Engine, But Valuation Is Rich

    Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.

    Aug 3·22 min